Sanofi, Regeneron Dupixent OKd in EU as the first-ever targeted therapy for COPD

 Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

• First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life
• Dupixent is the first new treatment approach for COPD in more than a decade and a new option for approximately 220,000 adults in the EU
• Approval represents the sixth approved indication for Dupixent in the EU and seventh approved indication globally

https://www.biospace.com/article/releases/press-release-dupixent-approved-in-the-eu-as-the-first-ever-targeted-therapy-for-patients-with-copd/